| 000 | 00935 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250511214456.0 | ||
| 264 | 0 | _c19900820 | |
| 008 | 199008s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/0140-6736(90)91720-u _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRodell, M B | |
| 245 | 0 | 0 |
_aSafety of monoclonal antibody purified factor VIII. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cJul 1990 |
||
| 300 |
_a188 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 |
_aFactor VIII _xadverse effects |
| 650 | 0 | 4 |
_aHepatitis C _xtransmission |
| 650 | 0 | 4 |
_aHepatitis, Viral, Human _xtransmission |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aProduct Surveillance, Postmarketing |
| 700 | 1 | _aBergman, G E | |
| 773 | 0 |
_tLancet (London, England) _gvol. 336 _gno. 8708 _gp. 188 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0140-6736(90)91720-u _zAvailable from publisher's website |
| 999 |
_c1979699 _d1979699 |
||